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co the Editor: Both obesity and heart failure (HF) are highly
revalent syndromes in modern Western society. Nearly 60% of
he U.S. population has a body mass index (BMI) 25 kg/m2 (1).
he incidence of HF approaches 10 per 1,000 among persons
lder than 65 years (2). Because both syndromes are highly
revalent, patients are likely to have both simultaneously.
Surprisingly, obese HF patients have a better prognosis than
ormal-weight HF patients, giving rise to the so-called obesity
aradox (3).
Brain natriuretic peptide (BNP) and aminoterminal proBNP
NT-proBNP) are established diagnostic markers in HF. How-
ver, it is unclear how to interpret the levels of BNP in overweight
atients, as BNP is cleared by the natriuretic peptide receptor
ype-C (NPR-C), which is abundantly expressed in adipocytes (4).
ndeed, a negative correlation has been described between BNP
nd BMI (5–7). Interestingly, a similar correlation was recently
escribed for NT-proBNP (8), which is not cleared by NPR-C.
o reliably address these relationships, we investigated the effect of
decrease in BMI following bariatric surgery on the concentra-
ions of BNP and NT-proBNP.
We studied 22 patients (5 men,17 women; median age 38 years)
eferred to our general surgery department for surgical treatment of
besity. Blood samples were collected one day before surgery, three
onths after surgery, and six months after surgery.
The medical history of the patients showed diabetes (n  6),
ypertension (n  4), and myocardial infarction (n  1). No
atient was known to have HF or be using diuretics, angiotensin-
onverting enzyme inhibitors, angiotensin receptor blockers, or
pironolactone during the study. Four patients were using beta-
lockers with no alternations during the study.
We confirm the correlation between BNP and NT-proBNP
ersus BMI in the combined consecutive measurements (r 
0.30, p  0.05; r  0.41, p  0.01, respectively). Body mass
ndex decreased drastically after three months (p  0.001) and six
onths (p  0.001), whereas BNP and NT-proBNP concentra-
ions significantly increased after three months (p 0.01 for both)
nd six months (p  0.01 for both) (Table 1).
Our study rejects the hypothesis that the negative correlation
etween BNP and BMI is due to an upregulation of NPR-C
ecause the NPR-C does not clear NT-proBNP. Given that both
eptides derive simultaneously from the cleavage of their common
redecessor proBNP, but are cleared via different mechanisms, the
arallel associations between peptide concentrations and BMI
uggest a relationship between adipose tissue and production.
able 1. Changes Over Time in Characteristics Within the Stud
t  0 Months t  3
NP (pg/ml) 4.5 (2.4–9.2) 13.4 (9
T-proBNP (pg/ml) 27 (19–38) 62 (4
ystolic blood pressure (mm Hg) 135 (130–145) 136 (1
iastolic blood pressure (mm Hg) 85 (80–90) 81 (7
ody weight (kg) 128 (109–146) 102 (8
ody mass index (kg/m2) 45 (41–48) 36 (3
reatinine (mol/l) 66 (61–72) 65 (5
ata are provided as medians with interquartile range (IQR). The Wilcoxon signed-ra
he patients. Spearman correlation coefficients were computed for correlation.
BNP  brain natriuretic peptide; NT-proBNP  aminoterminal proBNP.The negative correlation between BNP and BMI was already
nown from large observational studies (5–7). However, these
esults left room for different explanations. It has, for instance, been
ypothesized that obesity leads to an increase in NPR-C activity (4)
r that obesity causes a decrease in BNP production (9,10).
The finding that BNP and NT-proBNP increase simulta-
eously after weight loss suggests that obesity suppresses their
ommon production. This finding raises the question whether
heir suppression is caused by hindered production or reflects truly
ower wall stress. As both peptides are powerful predictors of
utcome (11,12), the evidence suggests the counterintuitive notion
hat lower (NT-pro)BNP concentrations herald a better prognosis
or obese subjects. Mehra et al. (6) found lower BNP levels in
bese versus non-obese HF patients with a non-significant ten-
ency toward a lower one-year event rate in the obese patients.
ther studies show a significantly better prognosis in obese HF
atients (3), suggesting that lowered (NT-pro)BNP levels indeed
eflect a more advantageous cardiac status.
Our data support findings by others concerning the regulation
f natriuretic peptides secretion in obesity. Morabito et al. (10)
how a decreased messenger ribonucleic acid expression of atrial
atriuretic peptide (ANP) in hearts of obese rats. Licata et al. (9)
ound a lack of ANP response and a reduced suppression of renine
nd aldosterone after saline load in obese subjects. We therefore
peculate that neurohumoral interactions are altered and decrease
atriuretic peptide production in obese subjects.
Our study is the first interventional study to show that a
ecrease in BMI is accompanied by an increase not only in BNP
ut also in NT-proBNP. This implies that there is a relationship
etween adipose tissue and the production of these peptides. It has
een suggested that lower BNP concentrations in obese subjects
re caused by an increased clearance. If this were true, we would
ave expected only BNP to rise after weight loss. However,
T-proBNP also rose after surgery. Taken together with the fact
hat both peptides derive simultaneously from their joint prede-
essor proBNP, the parallel increase suggests that production of
NP increases with decreasing weight.
This somewhat counterintuitive conclusion is in line with
revious studies and suggests that the previously reported negative
orrelation between BMI and (NT-pro)BNP cannot be explained
y inappropriate inclusion of severely obese subjects as having HF.
ur data are also congruent with the notion that obese HF
atients have a better prognosis, as lower BNP and NT-proBNP
oncentrations are powerful predictors of better outcome (11,12).
ients
hs t  6 Months
p Values
(0–3 Months)
p Values
(0–6 Months)
.1) 14.7 (8.7–22.7) p  0.01 p  0.01
) 90 (59–127) p  0.01 p  0.001
7) 132 (126–152) p  NS p  NS
80 (76–91) p  NS p  NS
) 97 (79–116) p  0.001 p  0.001
34 (29–41) p  0.001 p  0.001
66 (61–72) p  NS p  NS
was used to analyze differences between preoperative and postoperative values withiny Pat
Mont
.1–19
6–138
30–14
6–95)
7–133
3–41)
9–68)
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887JACC Vol. 47, No. 4, 2006 Correspondence
February 21, 2006:884–92aken together, our findings show that BNP and NT-proBNP
oncentrations increase with decreasing weight. This is likely to be
ue to decreased cardiac production of BNP, suggesting some yet
ndefined beneficial effects of obesity in HF that clearly warrant
urther study.
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The Underestimated Impact of Smoking and Smoking Cessation on the Risk of Secondary
Cardiovascular Disease Events in Patients With Stable Coronary Heart Disease:hort Studyo the Editor: Numerous studies have reported beneficial effects
f smoking cessation in terms of decreased cardiovascular morbid-
ty and mortality in patients with coronary heart disease (1).
owever, all of these studies primarily relied on self-reported
moking status. Additionally, changes in smoking status during
ollow-up were often not considered in the analysis. Both limita-
ions bear the potential for misclassification of smoking behavior
nd thus for dilution of differences between continuous smokers
nd quitters and for underestimation of the beneficial effect of
moking cessation. The aim of our analysis was to assess the impact
f smoking and smoking cessation on the risk of secondary cardio-
ascular disease (CVD) events by combining self-reported smoking
ata with measurements of a biomarker for active smoking (serum
otinine), and by accounting for changes in smoking status during the
ollow-up period.
We conducted a prospective cohort study among 1,206 patients
58% of eligible) age 30 to 70 years participating in a 3-week
n-patient rehabilitation (rehab) in two rehab clinics in Germany
everal weeks after acute manifestation of coronary heart disease
CHD) (2). Baseline data were collected at rehab admission and
ischarge, and active follow-up was conducted one and three years
fter rehab discharge. Four methods were used to categorize. Self-reported smoking status at the beginning of rehab only:
never smokers, former smokers (ex-smokers who had quit
before the acute manifestation of CHD), recent quitters
(ex-smokers who quit after the acute manifestation of CHD),
or continued smokers (smokers who did not quit until the
beginning of rehab).
. Serum cotinine levels at rehab discharge: 15 ng/ml 
smoker; 15 ng/ml  nonsmoker (3).
. Baseline smoking status based on both self-report and serum
cotinine measurements: Analogous to (A), but patients were
reclassified as continued smokers if they were cotinine positive
at rehab discharge, and self-reported continued smokers were
reclassified as recent quitters, if they were cotinine negative at
the end of rehab.
. Analogous to (C), but patients who changed smoking status
during follow-up (according to serum cotinine at one-year
follow-up) were excluded.
Secondary CVD events during follow-up were defined as death
rom CVD (International Classification of Diseases, 9th revision,
ositions 390 to 459) or a nonfatal myocardial infarction or
schemic cerebrovascular event (stroke or transient ischemic at-
ack), both as reported by the primary care physician.
